Publications | Lund University Publications

1 – 9 of 9

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22Lindman%2C+H.%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22Lindman%2C+H.%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2019
Mark Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series
Vallon-Christersson, Johan ^LU ; Häkkinen, Jari ^LU ; Hegardt, Cecilia ^LU ; Saal, Lao ^LU ; Larsson, Christer ^LU ; Ehinger, Anna ^LU ; Lindman, H ; Olofsson, Helena ; Sjoblom, Tobias and Wärnberg, Fredrik , et al. (2019) In Scientific Reports 9.
- Contribution to journal › Article
Mark Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
Lundgren, Christine ^LU ; Bendahl, Pär-Ola ^LU ; Ehinger, Anna ^LU ; Hegardt, Cecilia ^LU ; Larsson, Christer ^LU ; Loman, Niklas ^LU ; Malmberg, Martin ^LU ; Olofsson, Helena ; Saal, Lao ^LU and Sjoblom, Tobias , et al. (2019) In Breast Cancer Research and Treatment p.1-9
- Contribution to journal › Article
2018
Mark A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
Lindman, H. ; Andersson, M. ; Ahlgren, J. ; Balslev, E. ; Sverrisdottir, A. ; Holmberg, S. B. ; Bengtsson, N. O. ; Jacobsen, E. H. ; Jensen, A. B. and Hansen, J. , et al. (2018) In European Journal of Cancer 94. p.79-86
- Contribution to journal › Article
2011
Mark Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
Rosell, J. ; Nordenskjold, B. ; Bengtsson, N-O ; Fornander, T. ; Hatschek, T. ; Lindman, H. ; Malmström, Per ^LU ; Wallgren, A. ; Stal, O. and Carstensen, J. (2011) In British Journal of Cancer 104(6). p.899-902
- Contribution to journal › Article
2008
Mark Nordic Observational Study Evaluating Safety And Analgesic Use In Patients With Advanced Cancer Under Zoledronic Acid Treatment Interim Analysis
Lindman, H. ; Ostri, P. ; Andersen, M. ; Hagen, E. Krueger ; Wiklund, K. and Abrahamsson, Per-Anders ^LU (2008) 33rd European-Society-for-Medical-Oncology Congress In Annals of Oncology 19. p.255-255
- Contribution to journal › Published meeting abstract
Mark A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Margolin, S ; Carlsson, L ; Hellström, M ; Karlsson, P ; Lidbrink, E ; Linderholm, B ; Lindman, H ; Malmström, Per ^LU ; Sköld Pettersson, D and Bergh, J (2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117
- Contribution to journal › Published meeting abstract
2007
Mark Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Wilking, N. ; Lidbrink, E. ; Wiklund, T. ; Erikstein, B. ; Lindman, H. ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P. ; Bengtsson, N. -O. ; Soederlund, G. and Anker, G. , et al. (2007) In Annals of Oncology 18(4). p.694-700
- Contribution to journal › Article
2002
Mark A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin (R)) on a named patient basis in Sweden
Andersson, J ; Linderholm, B ; Greim, G ; Lindh, B ; Lindman, H ; Tennvall, Jan ^LU ; Tennvall-Nittby, L ; Pettersson-Skold, D ; Sverrisdottir, A and Soderberg, M , et al. (2002) In Acta Oncologica 41(3). p.276-281
- Contribution to journal › Article
2000
Mark Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
Bergh, J ; Wiklund, T ; Erikstein, B ; Lidbrink, E ; Lindman, H ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P ; Bengtsson, N O ; Söderlund, G and Anker, G , et al. (2000) In The Lancet 356(9239). p.1384-1391
- Contribution to journal › Article

your query:: Remove author: Lindman, H.